, Volume 89, Issue 1, pp 105-106
Date: 27 Jun 2009

Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

In the spring of 2005, a female patient aged 67 years at that time was referred to our service because of progressive haemoglobin decline. There was no history of bleeding. In 1997, in an external institution, bone marrow aspiration and cytogenetic analysis yielded the diagnosis of a myelodysplatic syndrome with a 5q-minus deletion (del5q), type 5q-minus syndrome (5q-Syn). Our laboratory tests revealed severe anaemia (haemoglobin 5 g/dL) as well as leucopenia [2.8 × 109/L (normal range, 3.7–9.6 × 109/L)], while overall neutrophil and thrombocyte counts were in the normal ranges. Given the symptomatic anaemia, erythrocyte concentrate transfusions were initiated. In May 2006, we started oral therapy with lenalidomide (10 mg/day for 21 days; 28-day cycle). Already by mid-July 2006, the patient had reached a haemoglobin value of 12 g/dL (Fig. 1). Until October 2006, four lenalidomide cycles were administered in total. Except for transient neutropenia grade III, no other side ef ...